Filtered By:
Drug: Plavix
Procedure: Percutaneous Coronary Intervention
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 387 results found since Jan 2013.
Comparative Safety and Effectiveness of Loading Doses of P2Y12 Inhibitors in Patients Undergoing Elective PCI: a Network Meta-analysis
ConclusionAlthough prasugrel and ticagrelor are known as more potent antiplatelet agents, their effects in preventing MI and stroke are marginal and do not translate into improved overall mortality and bleeding compared with clopidogrel.
Source: Cardiovascular Drugs and Therapy - October 13, 2021 Category: Cardiology Source Type: research
Comparison between preoperative loading dose with Ticagrelor and Clopidogrel on myocardial perfusion during intervention in patients with STsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention
ConclusionTicagrelor loading before primary PCI resulted in improved TIMI flow, MBG but did not decrease incidence of in-hospital MACE.
Source: QJM - October 1, 2021 Category: Internal Medicine Source Type: research
Bleeding Outcomes After Percutaneous Coronary Intervention in the Past Two Decades in Japan - From the CREDO-Kyoto Registry Cohort-2 and Cohort-3
CONCLUSIONS: In this historical comparative study, Cohort-3 compared with Cohort-2 was associated with excess bleeding risk, which might be at least partly explained by the difference in P2Y12receptor blockers.PMID:34526432 | DOI:10.1253/circj.CJ-21-0526
Source: Circulation Journal - September 16, 2021 Category: Cardiology Authors: Masahiro Natsuaki Takeshi Morimoto Hiroki Shiomi Ko Yamamoto Kyohei Yamaji Hirotoshi Watanabe Takashi Uegaito Mitsuo Matsuda Toshihiro Tamura Ryoji Taniguchi Moriaki Inoko Hiroshi Mabuchi Teruki Takeda Takenori Domei Manabu Shirotani Natsuhiko Ehara Hiros Source Type: research
P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial
CONCLUSIONS: P2Y₁₂ inhibitor monotherapy, mostly clopidogrel, following 3 months of DAPT did not increase ischemic events in patients with complex PCIs.PMID:34523115 | DOI:10.5603/CJ.a2021.0101
Source: Cardiology Journal - September 15, 2021 Category: Cardiology Authors: Ji Woong Roh Joo-Yong Hahn Ju-Hyeon Oh Woo Jung Chun Yong Hwan Park Woo Jin Jang Eul-Soon Im Jin-Ok Jeong Byung Ryul Cho Seok Kyu Oh Kyeong Ho Yun Deok-Kyu Cho Jong-Young Lee Young-Youp Koh Jang-Whan Bae Jae Woong Choi Wang Soo Lee Hyuck Jun Yoon Seung Uk Source Type: research
Antithrombotic therapy in high-risk patients after percutaneous coronary intervention; study design, cohort profile and incidence of adverse events
CONCLUSION: The high risk for both bleeding and ischaemic events in this cohort of patients with multiple clinical risk factors illustrates the challenges that the cardiologist faces to make a balanced decision on the optimal treatment strategy. This cohort will serve to answer several future research questions about the optimal management of these patients on dual/triple antithrombotic therapy, and the possible value of a wide range of laboratory tests to guide these decisions.PMID:34468944 | DOI:10.1007/s12471-021-01606-2
Source: Netherlands Heart Journal - September 1, 2021 Category: Cardiology Authors: R H Olie P E J van der Meijden M J A Vries L Veenstra A W J van 't Hof J M Ten Berg Y M C Henskens H Ten Cate Source Type: research
Effects of aging on clinical outcomes in patients receiving genotype ‐guided P2Y12 inhibitor selection after percutaneous coronary intervention
ConclusionThis study suggests important clinical benefits ofCYP2C19 genotype-guided antiplatelet therapy after PCI in both younger and older patients.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 21, 2021 Category: Drugs & Pharmacology Authors: Brian Wood,
Craig R. Lee,
Ian R. Mulrenin,
Megan N. Gower,
Joseph S. Rossi,
Karen E. Weck,
George A. Stouffer Tags: TI on Advances in Cardiovascular Pharmacotherapy Source Type: research
Effects of Aging on Clinical Outcomes in Patients Receiving Genotype ‐Guided P2Y12 Inhibitor Selection after Percutaneous Coronary Intervention
ConclusionThis study suggests important clinical benefits ofCYP2C19 genotype-guided antiplatelet therapy after PCI in both younger and older patients.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 10, 2021 Category: Drugs & Pharmacology Authors: Brian Wood,
Craig R. Lee,
Ian R. Mulrenin,
Megan N. Gower,
Joseph S. Rossi,
Karen E. Weck,
George A. Stouffer Tags: ORIGINAL RESEARCH Source Type: research
